Nursing Strategies to Optimize Treatment Experiences in Hormone-Receptor Positive, HER2-Negative Metastatic Breast Cancer

STATEMENT OF NEED

Breast cancer accounts for nearly 30% of cancer diagnoses among women in the United States, and is the second-leading cause of cancer death in this population. Although many women benefit from regular screening as well as earlier and improved treatment, approximately 10% present with metastatic disease, and 30% with no initial lymph node involvement eventually develop metastatic disease. Women with metastatic breast cancer (MBC) have a poorer prognosis than the overall population of breast cancer patients, and issues such as refractory or resistant disease, cumulative toxicities, adverse events, depression, and financial hardship are often encountered. Despite progress in understanding the pathogenesis of MBC and advances in therapy, the 5-year overall survival rate remains only 22%.

TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the management of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1. Describe patient- and disease-related factors that can inform individualized treatment planning in HR-positive, HER2-negative MBC
2. Differentiate therapeutic and safety profiles of CDK4/6 inhibitors in HR-positive, HER2-negative MBC
3. Apply supportive care strategies to mitigate adverse events associated with CDK4/6 inhibitors and promote adherence to therapy